Phase I/II, open-label, multiple ascending dose trial of AGEN2034, an anti–PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation in advanced cancer and expansion cohorts in subjects with relapsed/refractory cervical cancer

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 29; pp. viii412 - viii413
Main Authors Drescher, C., Moore, K.N., Liu, J.F., O’Malley, D.M., Wang, E.W., Wang, J.S.-Z., Subbiah, V., Wilky, B.A., Yuan, G., Dupont, C.D., Gonzalez, A.M., Savitsky, D., Coulter, S., Shebanova, O., Dow, E., Ortuzar, W., Buell, J.S., Stein, R.B., Youssoufian, H.
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.10.2018
Online AccessGet full text
ISSN0923-7534
1569-8041
1569-8041
DOI10.1093/annonc/mdy288.031

Cover

Author Drescher, C.
Subbiah, V.
Buell, J.S.
Youssoufian, H.
Shebanova, O.
Liu, J.F.
Wilky, B.A.
Wang, E.W.
Gonzalez, A.M.
Yuan, G.
O’Malley, D.M.
Wang, J.S.-Z.
Dupont, C.D.
Stein, R.B.
Coulter, S.
Moore, K.N.
Savitsky, D.
Dow, E.
Ortuzar, W.
Author_xml – sequence: 1
  givenname: C.
  surname: Drescher
  fullname: Drescher, C.
  organization: Gynecologic Oncology, Pacific Gynecology Specialists Seattle, Seattle, WA, USA
– sequence: 2
  givenname: K.N.
  surname: Moore
  fullname: Moore, K.N.
  organization: Gynecologic Oncology, Stephenson Cancer Center at the University of Oklahoma Health Sciences Center/Sarah Cannon Research Institute, Oklahoma City, OK, USA
– sequence: 3
  givenname: J.F.
  surname: Liu
  fullname: Liu, J.F.
  organization: Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
– sequence: 4
  givenname: D.M.
  surname: O’Malley
  fullname: O’Malley, D.M.
  organization: Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, OH, USA
– sequence: 5
  givenname: E.W.
  surname: Wang
  fullname: Wang, E.W.
  organization: Medical Oncology & Therapeutics Research, Penn State College of Medicine, Hershey, PA, USA
– sequence: 6
  givenname: J.S.-Z.
  surname: Wang
  fullname: Wang, J.S.-Z.
  organization: Medical Oncology, Sarah Cannon, Sarasota, FL, USA
– sequence: 7
  givenname: V.
  surname: Subbiah
  fullname: Subbiah, V.
  organization: Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
– sequence: 8
  givenname: B.A.
  surname: Wilky
  fullname: Wilky, B.A.
  organization: Department of Medicine, Division of Hematology/Oncology, Sylvester Comprehensive Cancer Center, Miami, FL, USA
– sequence: 9
  givenname: G.
  surname: Yuan
  fullname: Yuan, G.
  organization: Statistics, Agenus Bio, Inc., Lexington, MA, USA
– sequence: 10
  givenname: C.D.
  surname: Dupont
  fullname: Dupont, C.D.
  organization: Tcell Biology, Agenus Bio, Inc., Lexington, MA, USA
– sequence: 11
  givenname: A.M.
  surname: Gonzalez
  fullname: Gonzalez, A.M.
  organization: Translational Medicine, Agenus Bio, Inc., Lexington, MA, USA
– sequence: 12
  givenname: D.
  surname: Savitsky
  fullname: Savitsky, D.
  organization: Tcell Biology, Agenus Bio, Inc., Lexington, MA, USA
– sequence: 13
  givenname: S.
  surname: Coulter
  fullname: Coulter, S.
  organization: Clinical Operations, Agenus Bio, Inc., Lexington, MA, USA
– sequence: 14
  givenname: O.
  surname: Shebanova
  fullname: Shebanova, O.
  organization: Program and Portfolio Management, Agenus Bio, Inc., Lexington, MA, USA
– sequence: 15
  givenname: E.
  surname: Dow
  fullname: Dow, E.
  organization: Development Management, Agenus Bio, Inc., Lexington, MA, USA
– sequence: 16
  givenname: W.
  surname: Ortuzar
  fullname: Ortuzar, W.
  organization: Corporate Communications, Agenus Bio, Inc., Lexington, MA, USA
– sequence: 17
  givenname: J.S.
  surname: Buell
  fullname: Buell, J.S.
  organization: Communications and External Affairs, Agenus Bio, Inc., Lexington, MA, USA
– sequence: 18
  givenname: R.B.
  surname: Stein
  fullname: Stein, R.B.
  organization: Research Management, Agenus Bio, Inc., Lexington, MA, USA
– sequence: 19
  givenname: H.
  surname: Youssoufian
  fullname: Youssoufian, H.
  organization: Clinical Operations, Agenus Bio, Inc., Lexington, MA, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32137035$$D View this record in MEDLINE/PubMed
BookMark eNqNkU1uFDEQhS0URCaBA7BBPsB0xj89_QOrKCRhpAgiBOuW267JOHLbLbtnwuy4AzfMRaA6HZBgESFZslV-3yu73hE58MEDIa85O-GslgvlsaAXndmLqjphkj8jM74s6qxiOT8gM1YLmZVLmR-So5RuGWNFLeoX5FAKLksmlzPy83qjEtDVYrWa09CDz5xqwc1pt3WD7R1QlTR4Y_0NNQGVQ7TK0bCmp5fnHwWT-Zwqj2uw999_XL_POO2CD9oFj7Kx3Aazn1OLGrNTXoOhKThraKecvfFYsZDe0s-QsGEajR_aQNLKqcEG_xeqxy2ir6HwrVc-jQIdNiEii8K0bW9B4_nODhsawak-gVlEWEelhxD3FPGdRe9Hq5fk-Vq5BK8e92Py9eL8y9mH7OrT5ers9CrToqx4Vre8YNy0BeSlKPNctHxZLoXggpk1SKhqVoiqqMrWmLYFUeJNvQajdaGkgVweEzH5bn2v9nfKuaaPtlNx33DWjGk2U5rNlGaDaSL0ZoL6bduB-UP8jg8F5STQMaSEv2y0HR6mNkRl3ZPW_B_yf57zbmIAB7WzEJuE4Y252IhDb0ywT9C_AO803go
CitedBy_id crossref_primary_10_3390_jcm10194523
crossref_primary_10_3389_fonc_2022_904790
crossref_primary_10_1016_j_critrevonc_2023_103925
crossref_primary_10_2217_fon_2021_0529
crossref_primary_10_1016_j_ygyno_2021_08_018
crossref_primary_10_1007_s12032_022_01646_7
ContentType Journal Article
Copyright 2018 THE AUTHORS
Copyright_xml – notice: 2018 THE AUTHORS
DBID 6I.
AAFTH
AAYXX
CITATION
NPM
ADTOC
UNPAY
DOI 10.1093/annonc/mdy288.031
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
PubMed
Unpaywall for CDI: Periodical Content
Unpaywall
DatabaseTitle CrossRef
PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1569-8041
EndPage viii413
ExternalDocumentID 10.1093/annonc/mdy288.031
32137035
10_1093_annonc_mdy288_031
S0923753419496154
Genre Journal Article
GroupedDBID ---
-E4
.2P
.86
.I3
.XZ
.ZR
08P
0R~
0U7
1TH
23M
2WC
4.4
482
48X
53G
5GY
5VS
5WA
6.Y
6I.
6J9
70D
AABJS
AABMN
AAEDW
AAESY
AAFTH
AAIAV
AAIYJ
AAJKP
AAJQQ
AAKAS
AAKUH
AAMVS
AAOGV
AAPNW
AAUQX
AAXUO
ABEUO
ABIXL
ABJNI
ABKDP
ABLJU
ABNKS
ABOCM
ABQLI
ABQTQ
ABSAR
ABSMQ
ABVKL
ABZBJ
ACGFO
ACGFS
ACIMA
ACMRT
ACPQN
ACPRK
ACUFI
ACUTO
ADBBV
ADEIU
ADEYI
ADHKW
ADHZD
ADJQC
ADOCK
ADORX
ADQLU
ADRIX
ADRTK
ADYVW
ADZCM
ADZXQ
AEGPL
AEGXH
AEJOX
AEKPW
AEKSI
AEMDU
AENEX
AENZO
AEPUE
AEWNT
AFIYH
AFOFC
AFXEN
AGINJ
AGKEF
AGKRT
AGSYK
AHMBA
AHXPO
AIAGR
AIJHB
AIKOY
AITUG
ALMA_UNASSIGNED_HOLDINGS
ALUQC
AMRAJ
APIBT
APWMN
AQKUS
ASMCH
ASPBG
ATTQO
AVWKF
AWCFO
AXUDD
AZFZN
AZQFJ
BAWUL
BAYMD
BEYMZ
BGNMA
BGYMP
BHONS
BTRTY
BVRKM
BZKNY
C1A
CAG
CASEJ
CDBKE
CKLRP
COF
CS3
CZ4
DAKXR
DIK
DILTD
DL5
DPORF
DPPUQ
D~K
E3Z
EBS
EE~
EJD
EX3
F9B
FDB
FEDTE
GJXCC
GX1
H5~
HAR
HVGLF
HW0
HZ~
I09
IH2
IHE
IOX
J21
KAQDR
KC5
KDC
KOM
KOP
KQ8
KSI
KSN
LAK
M-Z
M41
M49
M4Y
MBLQV
MHKGH
N9A
NCXOZ
NGC
NOYVH
NTWIH
NU-
NU0
NVLIB
O9-
OAWHX
ODMLO
OJQWA
OK1
OVD
P2P
P6G
PAFKI
PB-
PEELM
PQQKQ
Q1.
Q5Y
QBD
R44
RD5
RNI
ROL
ROX
ROZ
RPX
RW1
RXO
RZC
RZE
RZF
RZO
SDH
TCURE
TEORI
TJX
TMA
TR2
U2A
W8F
WOQ
WOW
X7H
YAYTL
YFH
YKOAZ
ZKX
ZXP
~91
AAGQS
AALRI
AAYWO
AAYXX
ABNGD
ACUKT
ACVFH
ADCNI
ADVLN
AEHUL
AEUPX
AFJKZ
AFPUW
AFSHK
AGQPQ
AIGII
AKBMS
AKRWK
AKYEP
APXCP
CITATION
EFKBS
H13
AFETI
NPM
ADTOC
UNPAY
ID FETCH-LOGICAL-c2781-9b1601db6e4727442b157522120dfe3e890628687bddbbe272129fedcc6a3de43
IEDL.DBID UNPAY
ISSN 0923-7534
1569-8041
IngestDate Wed Oct 01 15:45:41 EDT 2025
Wed Feb 19 02:30:46 EST 2025
Thu Apr 24 22:54:35 EDT 2025
Thu Oct 16 04:30:41 EDT 2025
Fri Feb 23 02:48:13 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
License http://www.elsevier.com/open-access/userlicense/1.0
cc-by-nc-nd
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c2781-9b1601db6e4727442b157522120dfe3e890628687bddbbe272129fedcc6a3de43
OpenAccessLink https://proxy.k.utb.cz/login?url=https://academic.oup.com/annonc/article-pdf/29/suppl_8/mdy288.031/26140708/mdy288.031.pdf
PMID 32137035
ParticipantIDs unpaywall_primary_10_1093_annonc_mdy288_031
pubmed_primary_32137035
crossref_citationtrail_10_1093_annonc_mdy288_031
crossref_primary_10_1093_annonc_mdy288_031
elsevier_sciencedirect_doi_10_1093_annonc_mdy288_031
PublicationCentury 2000
PublicationDate October 2018
2018-10-00
2018-Oct
PublicationDateYYYYMMDD 2018-10-01
PublicationDate_xml – month: 10
  year: 2018
  text: October 2018
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Annals of oncology
PublicationTitleAlternate Ann Oncol
PublicationYear 2018
Publisher Elsevier Ltd
Publisher_xml – name: Elsevier Ltd
SSID ssj0006929
Score 2.2659364
SourceID unpaywall
pubmed
crossref
elsevier
SourceType Open Access Repository
Index Database
Enrichment Source
Publisher
StartPage viii412
Title Phase I/II, open-label, multiple ascending dose trial of AGEN2034, an anti–PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation in advanced cancer and expansion cohorts in subjects with relapsed/refractory cervical cancer
URI https://dx.doi.org/10.1093/annonc/mdy288.031
https://www.ncbi.nlm.nih.gov/pubmed/32137035
https://academic.oup.com/annonc/article-pdf/29/suppl_8/mdy288.031/26140708/mdy288.031.pdf
UnpaywallVersion publishedVersion
Volume 29
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1569-8041
  dateEnd: 20241102
  omitProxy: true
  ssIdentifier: ssj0006929
  issn: 0923-7534
  databaseCode: DIK
  dateStart: 19960101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 1569-8041
  dateEnd: 20241102
  omitProxy: true
  ssIdentifier: ssj0006929
  issn: 0923-7534
  databaseCode: GX1
  dateStart: 19960101
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lj9MwELZ2uxKcljcsgpUPnKBOEzsPm1sF-yjSVhWiUvcU-RWoCG3VtFq6J_4D_5A_AuM4KQuHXXFAqlQpGs8kmXHmG3s8g9ALLTLh6oCRJC0KEqdhQWSkLRGGq9BkSvK6dufZMD0dx-8myWQHnbdnYWSTFR60RxrkDMJg3WveI1mYokcFaAkwWs4hat9QzgOwzB6EAhCchFevBUC9i_bSBGB6B-2Nh6P-eV17jzICML3ecU5SQVwNnnbHU7BW5G8-N_qs2-vZQm4uZFlecU7Hd9Bl-1g-J-VzsF6pQF_-VfHxvzz3XbTfQFrc9zzuoR07u49unTWb9g_Qz9EncJV40BsMuth16yJgebbs4jaZEUtXUso5UWzmQFl3EsHzAvdPjoY0ZHEXyxn8VtMf376P3pIIw9yZ69IFEfVlNTebLp4CTZPRgGFGTQ3-AkHGR99_uHqN39sKBFaOcS3GVmCftWH-MVS7vyXwNdh-hW-lW07Ero_wEsYCYbVWbu2qwm4JG7uzQIvKmh5obVn3LtpgXX9_4d48q4dofHz04c0pafpOEE0zHhGhIghTjUptnLkCilRFAGopOPnQFJZZ7mo785RnyhilLIUgmorCGq1TyYyN2SPUAeXZJwgroagGDEVDwQEqFVwyFSduISBiXIrkAIWtZeW6KcrueoOUuU8OYLm3g9wrNwflHqCX2yELX5HkOuK4Nde8gVQeKuXgMa8b9tib9lYCoxED5wA3_Gpr6zeLf_pP1M9QZ7Vc2-eA8lbqEO2eTKLDZtb-AlrvV_c
linkProvider Unpaywall
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LbxMxELZKKsGpvGkRIB84QbwPex82twhaGqRGESJSe1r5tSViSaJsIkhP_Af-IX8ExuvdUDi04oAUKdJqPLO7M975xh7PIPRci1y4OmAkzcqSJFlUEhlrS4ThKjK5kryp3Xkyyo4nybvT9HQHnXVnYWSbFR50RxrkDMJgHbbvkSxMGVIBWgKMVnCI2jeU8wAsM4RQAIKT6PK1AKhvoN0sBZjeQ7uT0Xhw1tTeo4wATG92nNNMEFeDp9vxFKwT-ZvPtT7r1nq2kJsvsqouOaej2-iieyyfk_IpWK9UoC_-qvj4X577DtprIS0eeB530Y6d3UM3T9pN-_vo5_gjuEo8DIfDPnbdughYnq36uEtmxNKVlHJOFJs5UDadRPC8xIO3hyMasaSP5Qx-q-mPb9_Hb0iMYe7MdeWCiOaymptNH0-Bps1owDCjpgZ_hiDj3Pcfrl_h97YGgbVj3IixNdhnY5h_DNXubwl8DbZf4VvplhOx6yO8hLFAWK-VW7uqsVvCxu4s0KK2JgStLZveRRusm-8v3Jtn9QBNjg4_vD4mbd8JomnOYyJUDGGqUZlNcldAkaoYQC0FJx-Z0jLLXW1nnvFcGaOUpRBEU1Fao3UmmbEJe4h6oDy7j7ASimrAUDQSHKBSySVTSeoWAmLGpUgPUNRZVqHbouyuN0hV-OQAVng7KLxyC1DuAXqxHbLwFUmuIk46cy1aSOWhUgEe86phj7xpbyUwGjNwDnDDL7e2fr34x_9E_QT1Vsu1fQoob6WetfP1F1DPVwY
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Phase+I%2FII%2C+open-label%2C+multiple+ascending+dose+trial+of+AGEN2034%2C+an+anti%E2%80%93PD-1+monoclonal+antibody%2C+in+advanced+solid+malignancies%3A+Results+of+dose+escalation+in+advanced+cancer+and+expansion+cohorts+in+subjects+with+relapsed%2Frefractory+cervical+cancer&rft.jtitle=Annals+of+oncology&rft.au=Drescher%2C+C.&rft.au=Moore%2C+K.N.&rft.au=Liu%2C+J.F.&rft.au=O%E2%80%99Malley%2C+D.M.&rft.date=2018-10-01&rft.issn=0923-7534&rft.volume=29&rft.spage=viii412&rft.epage=viii413&rft_id=info:doi/10.1093%2Fannonc%2Fmdy288.031&rft.externalDBID=n%2Fa&rft.externalDocID=10_1093_annonc_mdy288_031
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0923-7534&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0923-7534&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0923-7534&client=summon